Monday 9 November 2026 Export PALI’s income statement to Excel — free account

Palisade Bio, Inc.

PALI

Healthcare Biotechnology

Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00.

Revenue: +19,900.0%
EPS: +91.4%
Free cash flow: −318.4%

Quarter to June 2026, against a year earlier

1.13 0.03 −2.59%

Follow PALI

Alert me

Market cap: $202.2M
P/E: 1.8×
Fwd P/E: n/m
Dividend yield: —
F-score: n/a
ROIC: 0.00%
Net debt / EBITDA: 7.4×
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Net sold: $123.4K
Trades: 4 sells · 6 buys
Ownership: 24.0%

Capital & Financial Ratios $m

Size

Market Cap 202

Revenue ttm 1

Net income ttm (32)

Free cash flow ttm (18)

Net debt Q (125)

Valuation

P/E 1.8

Forward P/E n/m

Price / sales 319.2

Forward P/S Powerpack

Price / FCF n/m

Price / book 2.0

Financial health

Current ratio Q 24.3

Debt / equity Q n/m

Interest coverage Q (10,748.0)

Growth

Revenue growth Q +19,900.0%

Operating income growth Q −311.5%

EPS, this year +25.3%

EPS, next year A −25.9%

Revenue, next year A −100.0%

EPS, past 5 yrs —

EPS, next 5 yrs A −3.7%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 50.88%

10-year low 10-year high

P/B against its own 10 years 62.95%

10-year low 10-year high

EV/Sales against its own 10 years 32.93%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	12	10	133	125
Receivables	—	—	—	1
Inventory	—	—	—	—
Other	—	—	—	—
	13	10	134	127

	2023	2024	2025	Q'26
Payables	1	1	1	2
ST’ Debt	0	0	0	—
Other	—	—	—	—
	3	3	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	(32.93%)	72.86%	(1.30%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	38.54%	0.00%	118.05%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.05 Actual −0.05

−0.66 −0.49 −0.31 −0.13 0.04

Q2 FY25 Miss −0.10

Q3 FY25 Miss −0.06

Q1 FY26 Miss −0.01

Q2 FY26 Met 0.00

Q3 FY26 — Nov 9

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY25	−0.48	−0.58	Miss by 0.10
Q3 FY25	−0.32	−0.38	Miss by 0.06
Q1 FY26	−0.04	−0.05	Miss by 0.01
Q2 FY26	−0.05	−0.05	Met by 0.00
Q3 FY26	−0.06	—	Reports 9 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.05)	—	—	—
’25	(0.47)	(0.58)	(0.38)	1.13	(0.30)
’24	(4.59)	(3.32)	(2.32)	(1.54)	(10.19)
’23	(8.10)	(7.95)	(7.35)	(4.80)	(26.99)
’22	(194.90)	(89.95)	(59.97)	99.62	(247.83)
’21	(1.09k)	(3.07k)	500.72	554.72	(2.54k)
’20	(4.18k)	(500.20)	(584.59)	(1.08k)	(2.79k)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	1	—	—	—
’23	0	—	—	—	0
’20	0	0	0	0	0
’19	0	0	0	0	0
’18	0	0	0	0	0
’17	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(8)	—	—	—
’25	(2)	(2)	(4)	(3)	(11)
’24	(3)	(3)	(3)	(2)	(12)
’23	(4)	(2)	(3)	(3)	(11)
’22	(4)	(3)	(3)	(3)	(13)
’21	(1)	(8)	(3)	(3)	(15)
’20	(2)	(1)	(1)	(2)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(8)	—	—	—
’25	(2)	(2)	(4)	(3)	(11)
’24	(3)	(3)	(3)	(2)	(12)
’23	(4)	(2)	(3)	(3)	(11)
’22	(4)	(3)	(3)	(3)	(13)
’21	(1)	(8)	(3)	(3)	(15)
’20	(2)	(1)	(1)	(2)	(5)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	0	0	0	—	—	0	—	—	1		+47.8%	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	(1,081.48)	0.00	0.00	100.00	—	—	95.63		0.0 pt	Powerpack Palisade Bio, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(21)	(16)	(5)	(8)	(10)	(27)	(14)	(12)	(14)	(17)	(32)		(2.5%)
	EBT margin, %	(130,090.12)	(6,025.38)	(1,894.08)	(54,231.82)	(76,555.56)	0.00	0.00	(4,920.00)	0.00	0.00	(4,230.60)		+130,090.1 pt
	Net income	(21)	(16)	(5)	(8)	(10)	(27)	(14)	(12)	(14)	(17)	(32)		(2.5%)
Per share, $
Per share, $	Revenue	162.00	298.52	257.31	30.80	3.65	0.00	0.00	0.55	0.00	0.00	0.00		n/m
	Earnings	(227,540.70)	(17,987.02)	(4,873.63)	(17,088.04)	(2,792.85)	(2,143.93)	(247.83)	(26.99)	(10.19)	(0.30)	0.65		(77.8%)
	Cash flow	(156,161.00)	(15,403.92)	(7,612.77)	(14,511.40)	(1,288.65)	(1,191.37)	(227.60)	(24.41)	(8.61)	(0.19)	(0.09)		(77.9%)
	Capex	(981.00)	(13.09)	(1.68)	0.00	(1.62)	0.00	(0.17)	(0.01)	0.00	0.00	0.00		n/m
	Free cash flow	(157,142.00)	(15,417.01)	(7,614.45)	(14,511.40)	(1,290.27)	(1,191.37)	(227.77)	(24.42)	(8.61)	(0.19)	(0.09)		(77.9%)
	Book value	113,308.00	9,776.68	5,986.98	10,252.00	(1,918.65)	593.95	212.59	24.81	5.29	2.32	0.58		(69.9%)
	Shares, m	0	0	0	0	0	0	0	0	1	56	121		+334.9%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	0.00	—	—	1.76		0.0
	P/S	2,246.04	70.26	10.84	144.63	1,085.26	—	—	20.86	—	—	319.17		596.3
	P/B	3.21	2.15	0.47	0.43	0.00	—	—	0.47	—	—	1.98		1.1
	EV/Sales	1,385.37	44.89	8.11	(175.76)	1,116.96	—	—	(26.44)	—	—	154.02		392.2
	EV/FCF	(1.43)	(0.87)	(0.27)	0.37	(3.16)	—	—	0.61	—	—	(6.39)		(0.8)
Cash, $m
Cash, $m	Operating cash flow	(16)	(13)	(8)	(7)	(5)	(15)	(13)	(11)	(12)	(11)	(18)		(4.0%)
	Capex	0	0	0	—	0	—	0	0	—	—	0		(36.7%)
	Free cash flow	(16)	(13)	(8)	(7)	(5)	(15)	(13)	(11)	(12)	(11)	(18)		(4.0%)
Balance, $m
Balance, $m	Working capital	14	11	5	4	(7)	9	12	11	7	130	122		+28.5%
	Net debt	(16)	(12)	(6)	(5)	0	(10)	(12)	(12)	(10)	(133)	(125)		+26.1%
	Shareholders’ equity	11	9	6	5	(7)	7	12	11	7	129	122		+31.1%
Returns, %
Returns, %	ROA	(112.24)	(85.87)	(45.66)	(117.07)	(214.98)	(342.75)	(100.87)	(82.62)	(115.82)	(23.11)	(47.68)		+89.1 pt
	ROIC	0.00	0.00	(1,966.55)	(2,809.80)	0.00	0.00	(5,340.01)	0.00	0.00	0.00	0.00		0.0 pt
	ROE	(258.77)	(158.04)	(67.72)	(149.62)	179.86	576.17	(143.75)	(103.55)	(153.59)	(24.52)	(51.37)		+234.2 pt
People
People	Employees	11	6	6	5	7	13	12	9	8	14	—		+2.7%
	Revenue/emp, $m	0.00	0.04	0.04	0.00	0.00	0.00	0.00	0.03	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SLGL Sol-Gel Technologies Ltd.	$206.3M	— (loss-making)	— (loss-making)	−96.58% (below 0%: shrinking)	n/m	−8.76% (below 0%: shrinking)	100.00%	(704.23%)	Compare
RNAC Cartesian Therapeutics, Inc.	$205.1M	— (loss-making)	— (loss-making)	−92.91% (below 0%: shrinking)	−7.84% (below 0%: shrinking)	−6.15% (below 0%: shrinking)	100.00%	0.00%	Compare
DRUG Bright Minds Biosciences Inc.	$204.2M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
PLX Protalix BioTherapeutics, Inc.	$202.2M	10.5×	10.6×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%	Compare
PALI Palisade Bio, Inc.	$202.2M	1.8×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)
ARTV Artiva Biotherapeutics, Inc.	$201.9M	— (loss-making)	— (loss-making)	—	n/m	+13.60% (above 0%: growing)	100.00%	0.00%	Compare
IKT Inhibikase Therapeutics, Inc.	$200.9M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%	Compare
ELDN Eledon Pharmaceuticals, Inc.	$199.9M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
IFRX InflaRx N.V.	$199.7M	— (loss-making)	— (loss-making)	−128.93% (below 0%: shrinking)	n/m	+59.76% (above 0%: growing)	14,029.95%	0.00%	Compare
Median of peers	$202.1M	—	—	−96.58%	—	−18.39%	80.50%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together less than 1%

RA Capital Management, L.P. 9.99%

Perceptive Advisors LLC 9.99%

Janus Henderson Investors US LLC 9.99%

Commodore Capital LP 8.49%

Point72 Capital Advisors, Inc. 6.33%

Octagon Capital Advisors LP 5.77%

Franklin Resources, Inc. 5.52%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Palisade Bio, Inc. (PALI) Latest News

28 Oct

Impact 4 · 8:32 AM · GlobeNewswire

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

20 Oct

Impact 4 · 8:05 AM · GlobeNewswire

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

12 Oct

Impact 4 · 8:05 AM · GlobeNewswire

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

28 Sep

Impact 3 · 8:50 AM · GlobeNewswire

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

27 Sep

Impact 4 · 1:01 PM · MarketBeat

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s

23 Sep

Impact 4 · 8:45 AM

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

22 Sep

Impact 4 · 8:35 AM · GlobeNewswire

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

21 Sep

Impact 3 · 9:00 AM · GlobeNewswire

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

10 Aug

Impact 4 · 4:20 PM

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

27 Jul

Impact 4 · 7:30 AM

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

29 Jun

Impact 4 · 8:30 AM

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

21 May

Impact 3 · 5:51 PM · The Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

12 May

Impact 3 · 4:15 PM

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

5 May

Impact 4 · 8:30 AM · GlobeNewswire

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

17 Apr

Impact 3 · 9:57 AM · Insider Monkey

Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile

31 Mar

Impact 4 · 2:35 PM · MarketBeat

Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals

Impact 3 · 2:50 PM

Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease

30 Mar

Impact 4 · 4:01 PM · GlobeNewswire

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

18 Mar

Impact 4 · 5:31 PM · Insider Monkey

Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients

1 Mar

Impact 4 · 6:30 AM · MarketBeat

Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference

23 Feb

Impact 4 · 8:40 AM · GlobeNewswire

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

29 Jan

Impact 4 · 8:45 AM · GlobeNewswire

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

16 Jan

Impact 3 · 8:30 AM

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

7 Jan

Impact 4 · 8:15 AM · GlobeNewswireMT NewswiresInsider MonkeyInsider MonkeyInsider MonkeyMT NewswiresSimply Wall St.MT Newswires

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

30 Dec

Impact 4 · 8:35 AM · GlobeNewswireInsider MonkeyMT NewswiresMT NewswiresMT NewswiresMT NewswiresInsider MonkeyMT Newswires

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

25 Dec

Impact 4 · 10:37 AM · Insider Monkey

Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results

19 Dec

Impact 4 · 12:00 PM

Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know

2 Dec

Impact 3 · 8:45 AM · GlobeNewswire

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

25 Nov

Impact 3 · 8:45 AM · GlobeNewswire

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

21 Nov

Impact 3 · 5:34 AM

Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Palisade Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Palisade Bio, Inc. (PALI) Latest News

28 Oct

20 Oct

12 Oct

28 Sep

27 Sep

23 Sep

22 Sep

21 Sep

10 Aug

27 Jul

29 Jun

21 May

12 May

5 May

17 Apr

31 Mar

30 Mar

18 Mar

1 Mar

23 Feb

29 Jan

16 Jan

7 Jan

30 Dec

25 Dec

19 Dec

2 Dec

25 Nov

21 Nov

Stockrow Weekly